Home
About us
What we do
How we work
Our strategy
History
Management
Discovery
Overview
Drug discovery
Discovery platform
Other programmes
Development
Overview
Cancer – Chk1 kinase
Autoimmune - TYK2/JAK1 kinases
Cancer - TYK2/JAK1 kinases
Cancer – Aurora+FLT3 kinase
Partners
Overview
Current collaborations
Investors
Document centre
Corporate governance
Share price and RNS
AIM rule 26
Advisers
News
Press releases
News archive
Events
Patents and publications
Presentations and press
Contact
Sitemap
Terms
Accessibility
Privacy and Cookies
Sitemap
Home
About us
What we do
How we work
Our strategy
History
Management
Discovery
Overview
Drug discovery
Discovery platform
Other programmes
Development
Overview
Cancer – Chk1 kinase
Autoimmune - TYK2/JAK1 kinases
Cancer - TYK2/JAK1 kinases
Cancer – Aurora+FLT3 kinase
Partners
Overview
Current collaborations
Investors
Document centre
Corporate governance
Share price and RNS
AIM rule 26
Advisers
News
Press releases
News archive
Events
Patents and publications
Presentations and press
Contact
@Sareumplc Latest tweet
RT
@HybridanLLP
: .
@Sareumplc
's (SAR) license partner provides Q2 operational update and outline of potential milestone payments on SRA737.…
via @Sareumplc
View more
